MYMD — MyMD Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- $59.99m
- $52.91m
- 41
- 15
- 30
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.27 | ||
| Price to Tang. Book | 7.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.73% | ||
| Return on Equity | -66.45% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.35 | 1.67 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.
Directors
- Joshua Silverman CHM (50)
- Chris Chapman PRE (68)
- Ian Rhodes CFO (48)
- Paul Rivard EVP (50)
- Adam Kaplin CSO (54)
- Craig Eagle DRC
- Jude Uzonwanne DRC
- Bill White IND (58)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- March 9th, 1989
- Public Since
- July 24th, 2008
- No. of Shareholders
- 750
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 39,470,009
- Address
- 855 N. WOLFE STREET, SUITE 623, BALTIMORE, 21205
- Web
- https://ir.mymd.com/
- Phone
- +1 8568488698
- Contact
- Robert Schatz
- Auditors
- Morison Cogen, LLP
Upcoming Events for MYMD
MyMD Pharmaceuticals Inc Extraordinary Shareholders Meeting
Q1 2023 MyMD Pharmaceuticals Inc Earnings Release
Q2 2023 MyMD Pharmaceuticals Inc Earnings Release
Similar to MYMD
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
FAQ
What is the MyMD Pharmaceuticals share price?
As of Today at 18:27 UTC, shares in MyMD Pharmaceuticals are trading at $1.52. This share price information is delayed by 15 minutes.
How has the MyMD Pharmaceuticals share price performed this year?
Shares in MyMD Pharmaceuticals last closed at $1.52 and the price had moved by -58.58% over the past 365 days. In terms of relative price strength the MyMD Pharmaceuticals share price has underperformed the S&P500 Index by -52.62% over the past year.
What are the analyst and broker recommendations for MyMD Pharmaceuticals?
There is no consensus recommendation for this security.
What is the MyMD Pharmaceuticals dividend yield?
MyMD Pharmaceuticals does not currently pay a dividend.
Does MyMD Pharmaceuticals pay a dividend?
MyMD Pharmaceuticals does not currently pay a dividend.
When does MyMD Pharmaceuticals next pay dividends?
MyMD Pharmaceuticals does not currently pay a dividend.
How do I buy MyMD Pharmaceuticals shares?
To buy shares in MyMD Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MyMD Pharmaceuticals?
As of the previous close price of $1.52, shares in MyMD Pharmaceuticals had a market capitalisation of $59.99m.
Where are MyMD Pharmaceuticals shares listed?
Here are the trading details for MyMD Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MYMD
What kind of share is MyMD Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum MyMD Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MyMD Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in MyMD Pharmaceuticals is $30.33. That is 1895.42% above the last closing price of $1.52.
Analysts covering MyMD Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the MyMD Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MyMD Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -36.98%.
As of the last closing price of $1.52, shares in MyMD Pharmaceuticals were trading -40.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MyMD Pharmaceuticals PE Ratio?
The MyMD Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.52.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MyMD Pharmaceuticals?
MyMD Pharmaceuticals' management team is headed by:
- Joshua Silverman - CHM
- Chris Chapman - PRE
- Ian Rhodes - CFO
- Paul Rivard - EVP
- Adam Kaplin - CSO
- Craig Eagle - DRC
- Jude Uzonwanne - DRC
- Bill White - IND